Clinical Trial Update: A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating the mTOR inhibitor sirolimus (Rapamune) for neurofibromatosis type 1–related plexiform neurofibromas has completed, with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type

Drugs mentioned

• Rapamune (sirolimus)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Neurofibromatosis Type 1 | Phase 2 | Status: COMPLETED | Results posted: 2017-02-14